Skip to main content
. 2016 May 23;34(20):2333–2340. doi: 10.1200/JCO.2015.64.8899

Fig 3.

Fig 3.

Estimated 5-year (A, B) overall survival (OS) and (C, D) progression-free survival (PFS) by molecular response at 3 months for both treatment arms. OS and PFS were calculated using patients on study treatment and in follow-up after discontinuation of randomly assigned treatment.